Broadsheet number 58: Homocysteine and disease

Pathology

Volumn 32, Issue 4, 2000, Pages 262-273

  Beilby, J ^a   Rossi, E ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; NEURAL TUBE DEFECT; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; THROMBOGENICITY; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION; ANIMAL; BLOOD; DIET; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIET; FOLIC ACID; HOMOCYSTEINE; HUMANS; NEURAL TUBE DEFECTS;

EID: 0033658593     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/pat.32.4.262.273     Document Type: Article

References (118)

1. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
2. Maternal hyperhomocysteinemia: A risk factor for neural-tube defects?
3. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study
4. Folate, vitamin B 12, and serum total homocysteine levels in confirmed Alzheimer disease PM
5. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy
6. Plasma homocysteine and cardiovascular disease
7. Homocysteine, vitamins and cardiovascular disease
8. Homocysteine and vitamins in cardiovascular disease
9. The metabolism of homocysteine: Pathways and regulation
10. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
11. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease
12. Assessment of homocysteine status
13. Homocystinuria due to cystathionine beta-synthase deficiency-the effects of betaine treatment in pyridoxine-responsive patients
14. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum
15. Rapid, fully automated measurement of plasma homocysteine with the Abbott IMx analyzer
16. Comparison of three different plasma homocysteine assays with gas chromatography-mass spectrometry
17. Method comparison for total plasma homocysteine between the Abbott IMx analyzer and an HPLC assay with internal standardization
18. Plasma total homocysteine in healthy subjects: Sex-specific relation with biological traits
19. Homocysteine and other thiols in plasma and urine: Automated determination and sample stability
20. Homocysteine in plasma: Stabilization of blood samples with fluoride
21. Total homocysteine in plasma or serum: Methods and clinical applications
22. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease
23. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation
24. Lifestyle determinants of plasma total homocysteine distribution: The Hordaland homocysteine study
25. Fasting and post-methionine homocyst(e)ine levels in a healthy Australian population
26. Biological variation and reference intervals for total plasma homocysteine
27. Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives
28. Homocysteine and coronary atherosclerosis
29. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria
30. Short-term and long-term variability of plasma homocysteine measurement
31. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population
32. Plasma homocysteine and menopausal status
33. Hyperhomocysteinemia in end-stage renal disease (ESRD): Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
34. Interactions between drugs and vitamins at advanced age
35. Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study
36. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study
37. Hyperhomocysteinemia in chronic alcoholism: Correlation with folate, vitamin B-12, and vitamin B-6 status
38. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy
39. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: A study of psoriasis patients receiving low-dose methotrexate treatment
40. Serial measures of plasma homocyst(e)ine after acute myocardial infarction
41. Plasma homocysteine in the acute and convalescent phases after stroke
42. Molecular genetics of methylenetetrahydrofolate reductase deficiency
43. Inherited disorders of vitamin-B12 utilization
44. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
45. Is the common 677C-T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis
46. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans
47. Methylenetetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease
48. The risk of carotid atherosclerosis with hyperhomocysteinemia and the C677T mutation of methylenetetrahydrfolate reductase. The Perth Carotid Ultrasound Assessment Study (CUDAS)
49. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation
50. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine,and risk of myocardial infarction in US physicians
51. Common methylenete-trahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
52. A second common mutation in methylenetetrahydrofolate reducatase gene: An additional risk factor for neural tube defect?
53. A common mutation a1298c in human methylenetetrahydrofolate reductase gene: Association with plasma total homocysteine and folate concentrations
54. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease
55. The identification of homocysteine in the urine
56. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland
57. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
58. The pathogenesis of coronary artery disease. A possible role for methionine metabolism
59. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women
60. Serum total homocysteine and coronary heart disease
61. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project
62. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
63. Plasma homocysteine and cardiovascular disease mortality
64. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial
65. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study
66. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
67. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis
68. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study
69. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients
70. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: A new link between diabetic nephropathy and cardiovascular disease?
71. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease
72. Hyperhomocysteinemia and the endocrine system: Implications for atherosclerosis and thrombosis
73. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
74. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study
75. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis
76. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
77. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?
78. Hyperhomocysteinemia and thrombosis: Acquired conditions
79. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
80. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
81. Coexistence of antithrombin deficiency, factor V Leiden and hyperhomocysteinemia in a thrombotic family
82. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506)
83. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis
84. Plasma homocysteine and mortality in patients with coronary artery disease
85. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: Findings in two populations at contrasting risk for coronary heart disease
86. Homocysteine mediated endothelial cell toxicity and its amelioration
87. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells
88. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats
89. Oxidation of low density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor
90. Inhibition of thrombomodulin surface expression and protein-C activation by the thrombogenic agent homocysteine
91. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
92. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells
93. Pathobiochemical implications of hyperhomocysteinemia
94. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations
95. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia
96. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study
97. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation
98. Maternal Plasma folate and vitamin B12 are independent risk factors for neural tube defects
99. Sequence analysis of the coding region of human methionine synthase: Relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease
100. Altered folate and vitamin B12 metabolism in families with spina bifida offspring
101. Folic acid: Influence on the outcome of pregnancy
102. Alzheimer disease: Protective factors
103. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?
104. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease
105. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease
106. The influence of dietary folate and methionine on the metabolic disposition of endotoxic homocysteine
107. Minimum effective dose of folic acid for food fortification to prevent neural-tube defects
108. Eat right and take a multivitamin
109. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
110. Vitamin requirements for the treatment of hyperhomocysteinemia in humans
111. Vitamins as homocysteine-lowering agents
112. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population
113. Effect of various regimens of vitamin B6 and folic acid on mild hyperhomocysteinemia in vascular patients
114. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia
115. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
116. Hyperhomocysteinemia and atherosclerotic vascular disease: Pathophysiology, screening, and treatment. off
117. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual?
118. An alternative view of homocysteine